Trial reportSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025
[Using Xiaoqinglong Decoction to Treat Acute Exacerbation of Chronic Obstructive Pulmonary Disease Presenting External Cold and Internal Fluid Retention Syndrome: Observation of the Clinical Efficacy].
Trial report in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To study the clinical efficacy of Xiaoqinglong decoction combined with the conventional protocol of western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) presenting with exterior cold and interior fluid retention syndrome, and to evaluate its effect on the short-term prognosis of patients. Methods: A total of 124 AECOPD patients presenting exterior cold and interior fluid retention syndrome were divided into an observation group (62 cases) and a control group (62 cases) using a random number table. Patients in the control and observation groups were managed with conventional western medicine treatment protocols consisting of bronchodilators, glucocorticoids, and antibacterial drugs. In addition, patients in the observation group were also given Xiaoqinglong decoction at one dose per day for 10 days in succession. The primary outcome indicators included the total effective treatment rate and the main traditional Chinese medicine (TCM) syndrome scores before treatment and after 10 days of Xiaoqinglong decoction treatment. The secondary outcome indicators included infection and inflammatory indicators, including white blood cell count (WBC), procalcitonin (PCT), interleukin (IL)-6, C-reactive protein (CRP), and arterial blood gas indicators, including arterial partial pressure of oxygen (PaO Results: Compared with baseline findings for the same group before treatment, the main TCM syndrome scores and the total score were reduced in both groups after treatment ( Conclusion: Xiaoqinglong decoction combined with the conventional protocol of western medicine deminstrates good clinical efficacy in treating patients with AECOPD of exterior cold and interior fluid retention syndrome, and can effectively improve the TCM syndromes, relieve the symptoms of dyspnea, reduce the inflammatory response, promote the resolution of infection, delay disease progression, improve short-term prognosis, and shows better safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.